🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The FDA just approved the immunotherapy afami-cel for adults with #synovial sarcoma based on a trial led by Memorial Sloan Kettering Cancer Center's Sandra P D'Angelo, MD. Fantastic news for patients! mskcc.org/news/immunothe…

🚨The FDA approved afami-cel in advanced synovial sarcoma! Want to dive deeper into SPEARHEAD-1 trial findings? 🔒Sign up to access our exclusive content & hear directly from Sandra P D'Angelo, MD of Memorial Sloan Kettering Cancer Center on how afami-cel is reshaping treatment. targetedonc.com/view/behind-th…

Afami-cel is now the first engineered cell therapy approved for a solid tumor, offering new hope for metastatic #synovialsarcoma patients. This marks a transformative moment in cancer care. bit.ly/3WKZR7g Sandra P D'Angelo, MD Memorial Sloan Kettering Cancer Center

FDA Grants Accelerated Approval to Afamitresgene Autoleucel (TECELRA) for Treating Advanced Synovial Sarcoma Sandra P D'Angelo, MD U.S. FDA The Lancet oncodaily.com/119494.html #Cancer #CancerCare #CellTherapy #FDA #OncoDaily #Oncology #Sarcoma #SolidTumor #Immunotherapy

Afami-cel is now the first engineered cell therapy approved for a solid tumor, offering new hope for metastatic #synovialsarcoma patients. This marks a transformative moment in cancer care. bit.ly/3WKZR7g Sandra P D'Angelo, MD Memorial Sloan Kettering Cancer Center

New #JITC article: A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses bit.ly/4gE7Yup Nathan Seligson Sandra P D'Angelo, MD

Overview in Nature Biotechnology discussing the recent landmark approval of the 1st #TCR gene therapy approval. Appreciate the opportunity to share our perspective alongside TCR aficionados including Phil Greenberg, @immatics and others. Memorial Sloan Kettering Cancer Center MSK Department of Medicine Parker Institute for Cancer Immunotherapy

Here’s a closer look at #JITC article: A multicenter, randomized, non-comparative, phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma: expansion cohorts & correlative analyses by Nathan Seligson Brian Van Tine William Tap Gary K. Schwartz Sandra P D'Angelo, MD 1/6

Phase 2 Study (JAVELIN Merkel 200): Biomarker analyses - avelumab for metastatic Merkel cell carcinoma. bit.ly/4ezM9um

The final countdown until #CTOS2024 meeting! 4 days full of great science and networking with #sarcoma experts - researchers, clinicians & patient advocates from around the world! If you can't join on-site, follow our social media and interact with colleagues using #CTOSTweeTOS

It's ok at #CTOS2024 to drag me to your poster to pitch your science for Clinical Cancer Research, it the most inspiring thing i get to do!!

Thrilled to share our article this Thanksgiving Eve! 🍂 With expansion of HLA-restricted therapies, we show HLA genotyping via NGS is accurate, streamlines cancer care, boosts trial access, and may reduce disparities. Embedding it in routine panels is key!jamanetwork.com/journals/jamao…

Join us in Boulder, CO April 3, 2025 for inaugural Rocky Mountain #Sarcoma Symposium! incredible speakers Sandra P D'Angelo, MD Jason Sicklick Richard Gorlick R. Lor Randall and Kaled Alektiar - register here: bit.ly/49v1gU5 time for ⛷️ afterwards! CU Cancer Center

Hear Sandra P D'Angelo, MD of Memorial Sloan Kettering Cancer Center and Nam Bui of Stanford Cancer Institute discuss developing targeted therapies that effectively address the SS18::SSX fusion oncogene and improving early detection methods. Watch more here: onclive.com/view/addressin…

🎙️Dr. Sandra D’Angelo highlights the IGNYTE-ESO trial, where Lete-cel shows a 42% response rate in synovial sarcoma and MRCLS, advancing sarcoma care oncodaily.com/url/221840 Sandra P D'Angelo, MD Amalya Sargsyan #Cancer #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

Had a great time visiting Regis today and speaking with students about recent advances in cancer research and my work in sarcoma treatment. Grateful for the warm welcome and thoughtful questions—future scientists in the making! #CancerResearch Regis High School Memorial Sloan Kettering Cancer Center

CTOS President Silvia Stacchiotti is inviting everyone to join the Annual Meeting in Boca Raton and celebrate 30th Anniversary of the Society! Get ready and prepare your abstracts! Especially on the #sarcoma of the year 🌟#chondrosarcoma #CTOS2025 #CTOSTweeTOS

Join sarcoma medical oncologist Sandra P D'Angelo, MD TODAY for her session on "Development of Afami-Cel–Engineered Cell Therapy for Advanced Synovial" at ASCO. #ASCO25 🗓️: 5/31 at 8:30am CT

Wonderful colleague and collaborator!

After one patient's synovial sarcoma returned, a clinical trial led MSK helped shrink his tumors by 85%. That same #Tcell therapy is now approved by the U.S. FDA. “This success story is just one example of MSK’s innovative approach to researching new treatments,” says MSK's